Neurocarrus

Treating Neurodegenerative Disease and Pain Without Addiction

https://wefunder.com/neurocarrus

Total raised on Wefunder: 544228

Total investors: 615

Quick facts

  • Drug candidate N-001 provides relief from acute pain in animals caused by inflammation or surgery.
  • Neurocarrus has built a pipeline of drugs using the APOLLO targeting and delivery system.
  • N-001, NL-17, N-19a treat acute, migraine and chronic pain by sensory neuron targeting.
  • The APOLLO drugs use a unique manufacturing process to discourage competitors.
  • There is a massive market for the treatment of Neurodegenerative disease and pain around the world.
  • Neurocarrus has a strong track record of non-dilutive funding from federal and state government.
  • Founder has been working in the space for 25+ years trouble shooting commercial biologicals.
  • Patents issued and pending on exclusively licensed technology in both the U.S. and select countries.

Team profiles

Featured investor profiles

Neurocarrus

Treating Neurodegenerative Disease and Pain Without Addiction

Funded badge
Last Funded May 2026

$544,228

raised from 615 investors

What Investors Say

LEAD INVESTOR
Invested $15,000 this round + $2,000 previously
I believe that Neurocarrus has the potential to revolutionize pain management. Paul and his team have created an incredibly clever drug the produces long lasting pain relief with no side effects or possibility of addiction. Neurocarrus’s N-001 has the potential to become the new standard of care for pain management, improving patient outcomes while eliminating the risk of opioid addiction. With backing from the National Institutes of Health, Neurocarrus is well on their way to changing the world of pain management and capturing a large portion of a market that approaches $80B/year.

What Friends Say

What People Say